Share Email Print
cover

Proceedings Paper

SnET2: clinical update
Author(s): Nicholas J. Razum; Albert B. Snyder; Daniel R. Doiron
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Tin Ethyl Etiopurpurin, SnET2, is a synthetic chlorin analog presently in Phase-II/III clinical trials for the treatment of cutaneous cancers. Trials to date include the treatment of basal cell carcinomas, squamous cell carcinomas, breast adenocarcinomas metastatic to the chest wall and cutaneous Kaposi's sarcomas in AIDS patients. Results to date have shown significant clinical responses for drug doses between 1.0 mg/kg and 1.6 mg/kg, with the threshold for Kaposi's sarcoma being slightly higher than in other indications. Light doses from 100 J/cm2 to 300 J/cm2 were delivered from 24 to 72 hours post SnET2 infusion. Induced transient skin photosensitivity at the lower therapeutic doses has been mild, lasting approximately a week. Results of the Phase I and II trials are presented.

Paper Details

Date Published: 2 April 1996
PDF: 4 pages
Proc. SPIE 2675, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy V, (2 April 1996); doi: 10.1117/12.237549
Show Author Affiliations
Nicholas J. Razum, PDT, Inc. (United States)
Albert B. Snyder, PDT, Inc. (United States)
Daniel R. Doiron, PDT, Inc. (United States)


Published in SPIE Proceedings Vol. 2675:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy V
Thomas J. Dougherty, Editor(s)

© SPIE. Terms of Use
Back to Top